@ARTICLE{
author={Sandborn William J,...,Jovanovic Igor,...,(broj koautora 16)},
year={2021},
title={Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis},
journal={NEW ENGLAND JOURNAL OF MEDICINE},
volume={385},
number={14},
pages={1280-1291},
document_type={Article},
} 

@ARTICLE{
author={Danese Silvio,Feagan Brian G,Hanauer Stephen B,Jovanovic Igor,Ghosh Subrata,Petersen Ann Katrin,Hua Steven,Lee Hwan Ji,Charles Lorna,Chitkara Denesh,Sandborn William J,D'Haens Geert},
year={2020},
title={Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={115},
number={},
pages={S8-S8},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Sandborn William J,D'Haens Geert,Wolf Doug,Hanauer Stephen B,Jovanovic Igor,Ghosh Subrata,Petersen Ann Katrin,Hua Steven,Lee Hwan Ji,Charles Lorna,Usiskin Keith,Danese Silvio,Feagan Brian G},
year={2020},
title={Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={115},
number={},
pages={S6-S7},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Danese Silvio,Feagan Brian G,Hanauer Stephen B,Jovanovic Igor,Ghosh Subrata,Petersen AnnKatrin,Hua Steven,Lee Hwan Ji,Charles Lorna,Chitkara Denesh,Sandborn William J,D'Haens Geert},
year={2020},
title={Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={115},
number={},
pages={S8-S8},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Sandborn William J,D'Haens Geert,Wolf Doug,Hanauer Stephen B,Jovanovic Igor,Ghosh Subrata,Petersen Ann Katrin,Hua Steven,Lee Hwan Ji,Charles Lorna,Usiskin Keith,Danese Silvio,Feagan Brian G},
year={2020},
title={Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={115},
number={},
pages={S6-S7},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Atreya Raja,Peyrin-Biroulet Laurent,Klymenko Andrii,Augustyn Monica,Bakulin Igor,Slankamenac Dusan S,Miheller Pal,Gasbarrini Antonio,Hebuterne Xavier,Arnesson Karin,Knittel Thomas,Kowalski Jan,Neurath Markus F,Sandborn William J,Reinisch Walter},
year={2020},
title={Cobitolimod for Moderate-to-Severe Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={115},
number={},
pages={S322-S322},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Atreya Raja,Peyrin-Biroulet Laurent,Klymenko Andrii,Augustyn Monica,Bakulin Igor,Slankamenac Dusan S,Miheller Pal,Gasbarrini Antonio,Hebuterne Xavier,Arnesson Karin,Knittel Thomas,Kowalski Jan,Neurath Markus F,Sandborn William J,Reinisch Walter},
year={2020},
title={Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial},
journal={LANCET GASTROENTEROLOGY & HEPATOLOGY},
volume={5},
number={12},
pages={1063-1075},
document_type={Article},
} 

@ARTICLE{
author={Reinisch Walter,Colombel Jean-Frederic,Gibson Peter R,Rutgeerts Paul,Sandborn William J,Tarabar Dino K,Huyck Susan,Khalifa Ahmed,Marano Colleen W,Philip George,Yao Ruji,Zhang Hongyan,Cornillie Freddy},
year={2019},
title={Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab},
journal={INFLAMMATORY BOWEL DISEASES},
volume={25},
number={1},
pages={163-171},
document_type={Article},
} 

@ARTICLE{
author={Sandborn William J,...,Tarabar Dino K,...,(broj koautora 20)},
year={2018},
title={Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study},
journal={GUT},
volume={67},
number={10},
pages={1824-+},
document_type={Article},
} 

@ARTICLE{
author={Reinisch Walter,Gibson Peter R,Sandborn William J,Feagan Brian G,Strauss Richard S,Johanns Jewel,Padgett Lakshmi,Adedokun Omoniyi J,Colombel Jean-Frederic,Collins Judith,Rutgeerts Paul,Tarabar Dino K,Marano Colleen W},
year={2018},
title={Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension},
journal={JOURNAL OF CROHNS & COLITIS},
volume={12},
number={9},
pages={1053-1066},
document_type={Article},
} 

@ARTICLE{
author={D'Haens Geert R,Reinisch Walter,Lee SD,Tarabar Dino K,Louis E,Klopocka M,Klaus J,Schreiber S,Park DI,Hebuterne Xavier,Cataldi F,Banerjee A,Gorelick K,Sandborn William J},
year={2018},
title={Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn's disease: the OPERA II study},
journal={JOURNAL OF CROHNS & COLITIS},
volume={12},
number={},
pages={S17-S18},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Feagan Brian G,Vermeire Severine,Sandborn William J,Reinisch Walter,Panes Julian,Tarabar Dino K,Su Chinyu,Niezychowski Wojciech,Zhang Haiying,Friedman Gary S,Woodworth Deborah A,Sands Bruce E},
year={2017},
title={Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={112},
number={},
pages={S329-S329},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Feagan Brian G,Vermeire Severine,Sandborn William J,Reinisch Walter,Tarabar Dino K,Su Chinyu,Niezychowski Wojciech,Zhang Haiying,Woodworth Deborah A,Yu Dahong,Sands Bruce E},
year={2016},
title={Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={111},
number={},
pages={S319-S320},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Gibson Peter R,Feagan Brian G,Sandborn William J,Marano Colleen W,Strauss Richard S,Johanns Jewel,Padgett Lakshmi,Collins Judith,Tarabar Dino K,Hebzda Zbigniew,Rutgeerts Paul,Reinisch Walter},
year={2016},
title={Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year},
journal={CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY},
volume={7},
number={},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Reinisch Walter,Gibson Peter R,Sandborn William J,Feagan Brian G,Marano Colleen W,Strauss Richard S,Johanns Jewel,Zhang Hongyan,Padgett Lakshmi,Adedokun Omoniyi J,Colombel J-F,Collins Judith,Rutgeerts Paul,Tarabar Dino K},
year={2016},
title={Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension},
journal={JOURNAL OF CROHNS & COLITIS},
volume={10},
number={},
pages={S248-S249},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Colombel J-F,Reinisch Walter,Gibson Peter R,Sandborn William J,Feagan Brian G,Xu S,Strauss Richard S,Zhang H,Tarabar Dino K,Hebzda Z,Rutgeerts Paul,Marano Colleen W},
year={2016},
title={Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome-post-hoc analyses from the PURSUIT programme},
journal={JOURNAL OF CROHNS & COLITIS},
volume={10},
number={},
pages={S56-S57},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Reinisch Walter,Sandborn William J,Feagan Brian G,Rutgeerts Paul,Gibson Peter R,Collins Judith,Tarabar Dino K,Hebzda Zbigniew,Colombel Jean-Frederic,Marano Colleen W,Strauss Richard S,Johanns Jewel,Zhang Hongyan},
year={2015},
title={Fecal Lactoferrin (fLac) and Calprotectin (fCal) as Surrogate Markers of Mucosal Healing: Post-hoc Analysis from the PURSUIT SC Induction Study},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={110},
number={},
pages={S791-S792},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Sandborn William J,Colombel Jean-Frederic,Reinisch Walter,Gibson Peter R,Feagan Brian G,Marano Colleen W,Strauss Richard S,Johanns Jewel,Zhang Hongyan,Weng Haoling,Yao Ruji,Tarabar Dino K,Hebzda Zbigniew,Rutgeerts Paul},
year={2014},
title={Clinical Outcomes in Continuous Clinical Responders with Moderately to Severely Active Ulcerative Colitis: Subanalyses from the PURSUIT-SC Maintenance Study},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={109},
number={},
pages={S505-S505},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Sandborn William J,Feagan Brian G,Marano Colleen W,Strauss Richard S,Johanns Jewel,Zhang Hongyan,Colombel Jean-Frederic,Reinisch Walter,Gibson Peter R,Collins Judith,Tarabar Dino K,Hebzda Zbigniew,Rutgeerts Paul},
year={2014},
title={Assessment of Fecal Markers and Clinical Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results from PURSUIT-SC Induction},
journal={AMERICAN JOURNAL OF GASTROENTEROLOGY},
volume={109},
number={},
pages={S502-S503},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Sandborn William J,Regula Jaroslaw,Feagan Brian G,Belousova Elena,Jojic Njegica Z,Lukas Milan,Yacyshyn Bruce,Krzeski Piotr,Yeh Chyon-Hwa,Messer Christi A,Hanauer Stephen B},
year={2009},
title={Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis},
journal={GASTROENTEROLOGY},
volume={137},
number={6},
pages={1934-1943},
document_type={Article},
} 

@ARTICLE{
author={Rutgeerts P,Sandborn William J,Fedorak RN,Rachmilewitz D,Tarabar Dino K,Gibson Peter R,Nielsen OH,Wild G,Schreiber S,Rossi CP,Zignani M},
year={2006},
title={Onercept for moderate-to-severe Crohn's disease: A randomized, double-blind, placebo-controlled trial},
journal={CLINICAL GASTROENTEROLOGY AND HEPATOLOGY},
volume={4},
number={7},
pages={888-893},
document_type={Article},
}